On to the next

Houston-based tech subsidiary moves its headquarters to new space

Houston-based Honeywell Process Solutions is moving down the road in order to expand its local presence. Courtesy of Parkway

A major technology solutions company announced its relocating it's Houston-based subsidiary to a bigger space. Fortune 100 company Honeywell has executed a long-term lease at CityWestPlace for Honeywell Process Solutions.

The company is relocating its Houston office from off Beltway 8 and Briar Forest to CityWestPlace Building 1, which is just south of its current office. The larger, 114,068-square-foot office space is expected to open by late 2019. The company will have 750 of its employees in the new building

"Parkway is thrilled to welcome Honeywell, a company with an extensive history and acclaimed reputation for creating exceptional products, solving complex problems through software solutions, and implementing cutting-edge technologies in a variety of industries including oil and gas, to CityWestPlace," says Parkway's senior leasing manager, J.P. Hutcheson, in a release.

CityWestPlace, which is operated by Parkway Property Investments, LLC, boasts of 1,473,177 rentable square feet across four campus buildings in Houston's Westchase District. Honeywell was represented by Rich Pancioli and John Morris with CBRE; JP Hutcheson led efforts on behalf of Parkway in the transaction.

The CityWestPlace campus spans 35 acres and has three dining spots, two fitness centers, and recreational offerings, such as a soccer field, outdoor track, sand volleyball court, indoor basketball court, horseshoe pit and bocce ball court.

Honeywell's new Houston office allows the company to expand.Courtesy of Parkway

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News